Revolution Medicines Stock
Revolution Medicines, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mark A. Goldsmith
- Employees
- 883
- Market cap
- $38.1 B
- IPO
- 13/02/2020
Revolution Medicines, Inc. (RVMD) operates in the healthcare/biotechnology sector and is headquartered in Redwood City, California. The company focuses on precision oncology to develop new treatments for RAS-driven cancers. Its pipeline includes drug candidates such as the SHP2 inhibitor RMC-4630, as well as RMC-5845…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Revolution Medicines stock: price history
1D
-6.0%
1W
-6.2%
1M
-9.2%
6M
+19.7%
YTD
+123.4%
1Y
+258.2%
2Y
+253.0%
5Y
+560.3%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~1% stronger price swings than usual
Revolution Medicines stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Revolution Medicines, Inc. is a clinical-stage biotechnology company operating in the field of precision oncology, focusing on the development of innovative therapies for RAS-driven cancers through targeted inhibition of specific protein pathways. The company is currently in an intensive research phase and is developing various drug candidates such as RMC-4630, RMC-5845, and RMC-5552 for diverse tumor types. The company currently generates all revenue from collaborations in the area of drug development.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
SanofiDescriptionAsk the agents about Revolution Medicines
Analyst assessment of Revolution Medicines
PRICE TARGET LOW
US$179.00
CONSENSUS
US$253.41
MEDIAN
US$260.00
PRICE TARGET HIGH
US$320.00
1
STRONG BUY
21
BUY
2
HOLD
0
SELL
0
STRONG SELL
24
TOTAL · Buy
As of: 15/10/2026
Revolution Medicines stock metrics
P/E
-20.09
P/B
14.4
EV/EBITDA
-22.46
RETURN ON EQUITY
-24.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.25
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.1%
FLOAT SHARES
193,042,361
AVG. DAILY VOLUME (30D)
2,149,967
Insider transactions (SEC)
Sandler Alan B.
Sandler Alan B.
Sandler Alan B.
Sandler Alan B.
Sandler Alan B.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.0%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Revolution Medicines stock
What does Revolution Medicines do?
Revolution Medicines, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mark A. Goldsmith, the company employs around 883 people.
The IPO was on 13/02/2020; the stock trades on NASDAQ under the ticker RVMD.
What do analysts say about Revolution Medicines stock?
24 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$253.41, ranging from US$179.00 to US$320.00, with a median of US$260.00.
This is an external assessment, not a statement by Market Jury.
When does Revolution Medicines report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Revolution Medicines pay a dividend?
No, Revolution Medicines currently does not pay a dividend.
Which stocks are comparable to Revolution Medicines?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Incyte, Exelixis, Neurocrine Biosciences, Summit Therapeutics and Halozyme Therapeutics.
How can I get Revolution Medicines stock analyzed?
Clicking "Analyze stock" lets five strategies assess Revolution Medicines against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.